

Louis Potters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9537519/publications.pdf>

Version: 2024-02-01

116
papers

6,333
citations

87888

38
h-index

66911

78
g-index

126
all docs

126
docs citations

126
times ranked

4077
citing authors

#	ARTICLE	IF	CITATIONS
1	American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Performance of Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2010, 76, 326-332.	0.8	473
2	Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≤72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. International Journal of Radiation Oncology Biology Physics, 2004, 58, 25-33.	0.8	440
3	Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation. International Journal of Radiation Oncology Biology Physics, 2007, 67, 327-333.	0.8	440
4	American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy, 2012, 11, 6-19.	0.5	399
5	12-YEAR OUTCOMES FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2005, 173, 1562-1566.	0.4	275
6	Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. International Journal of Radiation Oncology Biology Physics, 1999, 45, 59-67.	0.8	255
7	A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2001, 50, 605-614.	0.8	248
8	Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology, 2001, 58, 393-399.	1.0	199
9	American Society for Therapeutic Radiology and Oncology* and American College of Radiology Practice Guideline for the Performance of Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1026-1032.	0.8	191
10	Potency after permanent prostate brachytherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 2001, 50, 1235-1242.	0.8	182
11	Monotherapy for stage T1–T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiotherapy and Oncology, 2004, 71, 29-33.	0.6	172
12	Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2000, 48, 119-124.	0.8	167
13	Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: Executive summary. Practical Radiation Oncology, 2012, 2, 2-9.	2.1	164
14	12-Year Outcomes Following Permanent Prostate Brachytherapy in Patients with Clinically Localized Prostate Cancer. Journal of Urology, 2008, 179, S20-4.	0.4	146
15	Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7–10 Prostate Cancer Treated With Permanent Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2009, 73, 341-346.	0.8	126
16	Examining the Role of Neoadjuvant Androgen Deprivation in Patients Undergoing Prostate Brachytherapy. Journal of Clinical Oncology, 2000, 18, 1187-1192.	1.6	125
17	Vitexins, Nature-Derived Lignan Compounds, Induce Apoptosis and Suppress Tumor Growth. Clinical Cancer Research, 2009, 15, 5161-5169.	7.0	118
18	Comparison of biochemical failure definitions for permanent prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1487-1493.	0.8	110

#	ARTICLE	IF	CITATIONS
19	Choosing Wisely: The American Society for Radiation Oncology's Top 5 list. <i>Practical Radiation Oncology</i> , 2014, 4, 349-355.	2.1	102
20	Customized Dose Prescription for Permanent Prostate Brachytherapy: Insights From a Multicenter Analysis of Dosimetry Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1472-1477.	0.8	92
21	American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Stereotactic Radiosurgery (SRS). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 310-315.	1.3	91
22	American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Image-Guided Radiation Therapy (IGRT). <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 319-325.	0.8	90
23	A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, 2345-2367.	2.8	81
24	Critical organ dosimetry in permanent seed prostate brachytherapy: Defining the organs at risk. <i>Brachytherapy</i> , 2005, 4, 186-194.	0.5	80
25	The definition of biochemical failure in patients treated with definitive radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 1469-1474.	0.8	69
26	American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Transperineal Permanent Brachytherapy of Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 335-341.	0.8	68
27	Diminished Survival of Young Blacks With Adenocarcinoma of the Prostate. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1990, 13, 465-469.	1.3	63
28	Importance of implant dosimetry for patients undergoing prostate brachytherapy. <i>Urology</i> , 2003, 62, 1073-1077.	1.0	63
29	Postoperative Nomogram Predicting the 9-Year Probability of Prostate Cancer Recurrence After Permanent Prostate Brachytherapy Using Radiation Dose as a Prognostic Variable. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1061-1065.	0.8	59
30	Isotope selection for patients undergoing prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 391-395.	0.8	56
31	Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States. <i>Brachytherapy</i> , 2007, 6, 2-8.	0.5	47
32	Common error pathways seen in the RO-ILS data that demonstrate opportunities for improving treatment safety. <i>Practical Radiation Oncology</i> , 2018, 8, 123-132.	2.1	45
33	Long-Term Outcomes in Younger Men Following Permanent Prostate Brachytherapy. <i>Journal of Urology</i> , 2009, 181, 1665-1671.	0.4	44
34	Establishing High-Quality Prostate Brachytherapy Using a Phantom Simulator Training Program. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 579-586.	0.8	43
35	Six sigma tools for a patient safety-oriented, quality-checklist driven radiation medicine department. <i>Practical Radiation Oncology</i> , 2012, 2, 86-96.	2.1	42
36	Impact of Intraoperative Edema During Transperineal Permanent Prostate Brachytherapy on Computer-Optimized and Preimplant Planning Techniques. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, e130-e135.	1.3	41

#	ARTICLE	IF	CITATIONS
37	Prospective contouring rounds: A novel, high-impact tool for optimizing quality assurance. <i>Practical Radiation Oncology</i> , 2015, 5, e431-e436.	2.1	41
38	Toward a dynamic real-time intraoperative permanent prostate brachytherapy methodology. <i>Brachytherapy</i> , 2003, 2, 172-180.	0.5	40
39	Physician Attitudes and Practices Related to Voluntary Error and Near-Miss Reporting. <i>Journal of Oncology Practice</i> , 2014, 10, e350-e357.	2.5	39
40	Locally advanced paranasal sinus and nasopharynx tumors treated with hyperfractionated radiation and concomitant infusion cisplatin. <i>Cancer</i> , 1991, 67, 2748-2752.	4.1	37
41	Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing. <i>Brachytherapy</i> , 2016, 15, 274-282.	0.5	37
42	Pelvic control following external beam radiation for surgical stage I endometrial adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 33, 851-854.	0.8	32
43	Synuclein β Stimulates Membrane-Initiated Estrogen Signaling by Chaperoning Estrogen Receptor (ER) β 36, a Variant of ER β . <i>American Journal of Pathology</i> , 2010, 177, 964-973.	3.8	30
44	Practice-Based Evidence to Evidence-Based Practice: Building the National Radiation Oncology Registry. <i>Journal of Oncology Practice</i> , 2013, 9, e90-e95.	2.5	29
45	The prognostic significance of Gleason grade in patients treated with permanent prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 749-754.	0.8	28
46	Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1014-1019.	0.8	26
47	Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. <i>Brachytherapy</i> , 2021, 20, 1114-1129.	0.5	26
48	Incident Learning and Failure-Mode-and-Effects-Analysis Guided Safety Initiatives in Radiation Medicine. <i>Frontiers in Oncology</i> , 2013, 3, 305.	2.8	23
49	Permanent prostate brachytherapy: Dosimetric results and analysis of a learning curve with a dynamic dose-feedback technique. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 694-698.	0.8	22
50	Implementation of a "No Fly" safety culture in a multicenter radiation medicine department. <i>Practical Radiation Oncology</i> , 2012, 2, 18-26.	2.1	22
51	Implementation of Telehealth in Radiation Oncology: Rapid Integration During COVID-19 and Its Future Role in Our Practice. <i>Advances in Radiation Oncology</i> , 2021, 6, 100575.	1.2	20
52	Assessment of External Beam Radiation Technology for Dose Escalation and Normal Tissue Protection in the Treatment of Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 671-677.	0.8	19
53	A Systems Approach Using Big Data to Improve Safety and Quality in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 885-889.	0.8	19
54	Guidelines to Reduce Hospitalization Rates for Patients Receiving Curative-Intent Radiation Therapy During the COVID-19 Pandemic: Report From a Multicenter New York Area Institution. <i>Advances in Radiation Oncology</i> , 2020, 5, 621-627.	1.2	19

#	ARTICLE	IF	CITATIONS
55	Development, Implementation, and Compliance of Treatment Pathways in Radiation Medicine. <i>Frontiers in Oncology</i> , 2013, 3, 105.	2.8	18
56	Prospective Peer Review in Radiation Therapy Treatment Planning: Long-Term Results From a Longitudinal Study. <i>Practical Radiation Oncology</i> , 2020, 10, e199-e206.	2.1	18
57	A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma. <i>Cancer</i> , 2002, 95, 1451-1456.	4.1	17
58	External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer. <i>Brachytherapy</i> , 2002, 1, 36-41.	0.5	17
59	Deformable image registration and interobserver variation in contour propagation for radiation therapy planning. <i>Journal of Applied Clinical Medical Physics</i> , 2016, 17, 347-357.	1.9	17
60	Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 282-289.	0.8	16
61	Comprehensive management including interstitial brachytherapy for locally advanced or recurrent gynecologic malignancies. <i>Gynecologic Oncology</i> , 1992, 46, 322-325.	1.4	14
62	How one defines intensity-modulated radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 609-610.	0.8	14
63	Stereotactic Body Radiation Therapy. <i>Journal of the American College of Radiology</i> , 2005, 2, 676-680.	1.8	13
64	Defining the value of magnetic resonance imaging in prostate brachytherapy using time-driven activity-based costing. <i>Brachytherapy</i> , 2017, 16, 665-671.	0.5	13
65	Implementation and utilization of hypofractionation for breast cancer. <i>Advances in Radiation Oncology</i> , 2018, 3, 265-270.	1.2	13
66	Impact of Multi-Institutional Prospective Peer Review on Target and Organ-at-Risk Delineation in Radiation Therapy. <i>Practical Radiation Oncology</i> , 2019, 9, e228-e235.	2.1	13
67	Impact of the COVID-19 Pandemic Surge on Radiation Treatment: Report From a Multicenter New York Area Institution. <i>JCO Oncology Practice</i> , 2021, 17, e1270-e1277.	2.9	13
68	The role of external beam irradiation in patients undergoing prostate brachytherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2000, 5, 112-117.	1.6	12
69	In vivo dosimetry with optically stimulated luminescent dosimeters for conformal and intensity-modulated radiation therapy: A 2-year multicenter cohort study. <i>Practical Radiation Oncology</i> , 2017, 7, e135-e144.	2.1	12
70	Preventing Discontinuation of Radiation Therapy: Predictive Factors to Improve Patient Selection for Palliative Treatment. <i>Journal of Oncology Practice</i> , 2017, 13, e782-e791.	2.5	12
71	A theoretical derivation of the nomograms for permanent prostate brachytherapy. <i>Medical Physics</i> , 2001, 28, 683-687.	3.0	11
72	Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase 1 Trial for Patients With Low- and Intermediate-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 334-342.	0.8	10

#	ARTICLE	IF	CITATIONS
73	A chronological database to support outcomes research in prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 1252-1258.	0.8	9
74	Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1299-1307.	0.8	9
75	The second decade of prostate brachytherapy: Evidence and cost based outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 86-90.	1.6	9
76	Accuracy evaluation of a six-degree-of-freedom couch using cone beam CT and IsoCal phantom with an in-house algorithm. <i>Medical Physics</i> , 2017, 44, 3888-3898.	3.0	9
77	Improving efficiency and safety in external beam radiation therapy treatment delivery using a Kaizen approach. <i>Practical Radiation Oncology</i> , 2017, 7, e499-e506.	2.1	9
78	Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1232-1242.	0.8	9
79	Our Pledge to Achieve Safety. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1310-1311.	0.8	7
80	Disease Site-Specific Guidelines for Curative Radiation Treatment During "Limited Surgery" and "Hospital Avoidance": A Radiation Oncology Perspective From the Epicenter of COVID-19 Pandemic. <i>Cureus</i> , 2020, 12, e8190.	0.5	7
81	Automated health chats for symptom management of head and neck cancer patients undergoing radiation therapy. <i>Oral Oncology</i> , 2021, 122, 105551.	1.5	7
82	The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy. <i>Brachytherapy</i> , 2003, 2, 26-31.	0.5	6
83	A multicenter study demonstrating discordant results from electronic prostate-specific antigen biochemical failure calculation systems. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1494-1500.	0.8	6
84	Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation. <i>BJU International</i> , 2007, 99, 1066-1071.	2.5	6
85	The Paradox of Multidisciplinary Care. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 20-22.	0.8	6
86	Development and execution of a pandemic preparedness plan: Therapeutic medical physics and radiation dosimetry during the COVID-19 crisis. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 259-265.	1.9	6
87	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 953-963.	0.8	6
88	Computed tomography-based flap brachytherapy for non-melanoma skin cancers of the face. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 51-58.	0.9	6
89	Restructuring Our Approach to Peer Review: A Critical Need to Improve the Quality and Safety of Radiation Therapy. <i>Practical Radiation Oncology</i> , 2020, 10, 321-323.	2.1	5
90	Implementation of External Beam Five-Fraction Adjuvant Breast Irradiation in a US Center. <i>Cancers</i> , 2022, 14, 1556.	3.7	5

#	ARTICLE	IF	CITATIONS
91	Research on Quality and Safety: What Are We Missing?. International Journal of Radiation Oncology Biology Physics, 2015, 91, 17-19.	0.8	4
92	Posttraumatic Growth in Radiation Medicine During the COVID-19 Outbreak. Advances in Radiation Oncology, 2022, 7, 100975.	1.2	4
93	The Resilience of Radiation Oncology in the COVID Era and Beyond. International Journal of Radiation Oncology Biology Physics, 2020, 108, 364-369.	0.8	3
94	A Model-based method for assessment of salivary gland and planning target volume dosimetry in volumetric-modulated arc therapy planning on head-and-neck cancer. Journal of Medical Physics, 2019, 44, 201.	0.3	3
95	Non-adherence to multi-modality cancer treatment guidelines in the United States. Advances in Radiation Oncology, 2022, 7, 100938.	1.2	3
96	Biological effective dose in analysis of rectal dose in prostate cancer patients who underwent a combination therapy of VMAT and LDR with hydrogel spacer insertion. Journal of Applied Clinical Medical Physics, 2022, , e13584.	1.9	3
97	American Society for Radiation Oncology's Performance Assessment for the Advancement of Radiation Oncology Treatment: A practical approach for informing practice improvement. Practical Radiation Oncology, 2013, 3, e37-e43.	2.1	2
98	The dangers of incorporating reimbursement data into clinical decision making. Practical Radiation Oncology, 2015, 5, 274-276.	2.1	2
99	The Top Concerns of Radiation Oncology Trainees in 2019: A Response from SCAROP. International Journal of Radiation Oncology Biology Physics, 2020, 106, 26-28.	0.8	2
100	When in a Hole, Stop Digging. International Journal of Radiation Oncology Biology Physics, 2021, 110, 272-273.	0.8	2
101	Nomograms for clinically localized prostate cancer. Part II: Radiation therapy. Urologic Oncology, 2002, 20, 131-139.	1.5	2
102	Assessing initial plan check efficacy using TG 275 failure modes and incident reporting. Journal of Applied Clinical Medical Physics, 2022, , e13640.	1.9	2
103	The Art of Radiation Oncology?. International Journal of Radiation Oncology Biology Physics, 2007, 68, 966-967.	0.8	1
104	LONG-TERM OUTCOMES IN YOUNGER MEN FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY. Journal of Urology, 2009, 181, 210-210.	0.4	1
105	The safety hazard. Practical Radiation Oncology, 2014, 4, 215-216.	2.1	1
106	Iodine-125 vs. Palladium-103: Long-term complications. , 2000, 90, 110-110.		0
107	In Reply to Drs. Oton and Oton. International Journal of Radiation Oncology Biology Physics, 2008, 71, 962-963.	0.8	0
108	Radiation therapy approaches to the treatment of high-risk prostate cancer. Current Prostate Reports, 2009, 7, 95-101.	0.1	0

#	ARTICLE	IF	CITATIONS
109	Radiation therapy approaches to the treatment of high-risk prostate cancer. Current Urology Reports, 2009, 10, 187-193.	2.2	0
110	Apples to apples. Brachytherapy, 2011, 10, 15.	0.5	0
111	VALIDATION AND COMPARISON OF THE TWO KATTAN NOMOGRAMS IN PATIENTS WITH PROSTATE CANCER TREATED WITH ¹²⁵ IODINE BRACHYTHERAPY. BJU International, 2012, 109, 1665-1665.	2.5	0
112	In Reply to Baer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 897.	0.8	0
113	Is a Half-Truth a Whole Lie?. Journal of Oncology Practice, 2013, 9, 63-64.	2.5	0
114	Commentary in reply to: Gross et al, Radiation Oncologists'™ Role in End-of-Life Care: A Perspective From Medical Oncologists. Practical Radiation Oncology, 2019, 9, 371-372.	2.1	0
115	SCAROP Letter to Academic Chairs: Racial Justice and Health Equity. International Journal of Radiation Oncology Biology Physics, 2021, 109, 36-37.	0.8	0
116	Comparison of True Cost Between Modalities in a Changing American Healthcare System. , 2016, , 105-118.		0